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Abstract-Studies were performed to test whether 9-/l-D-arabinofuranosyladenine (ara-A) 
would accumulate in erythrocytes as a result of phosphorylation to the nucleotide level. 
When C3H]ara-A was incubated with whole blood from rat, monkey or man for 2 hr at 37”, 
the drug rapidly equilibrated between erythrocytes and plasma but did not concentrate in 
the cells. Incubation of C3H]ara-A with rat and human erythrocyte lysates for 2 hr followed 
by chromato~aphic analysis showed that 2-5 per cent of ara-A was converted to nucleo- 
tides. In contrast, 10-35 per cent of [‘YY]adenosine was converted to adenine nucteotides 
under the same conditions. Incubation of C3H]ara-A with human erythrocyte lysates for 
18 hr resulted in a conversion of approx. 40 per cent of the labeled drug to nucleotides. Ad- 
ditional chromatography revealed, however, that the nucleotide fraction contained almost 
no arabinosyl nucleotides. Rather, 90 per cent of the label in the nucleotide fraction was 
identified as IMP. These results indicate that only a minor amount, if any, of ara-A was 
phosphorylated by erythrocyte enzymes to yield arabinosyl nucleotides. An alternative 
pathway converted much of the labeled drug to ribosyl nucleotides via the deamination of 
ara-A to ara-hypoxanthine, cleavage to hypoxanthine and conversion of the free hypoxan- 
thine to IMP. 
MANY nucleoside antibiotics require conversion to the corresponding S-phosphates 
to express antineoplastic or antiviral activity. Conversion to the nucleotide can occur 
in either host tissues, tumor cells or viruses. ‘*’ Phosphorylation by host tissues will 
produce a compound active against not only the tumor or virus, but also against 
proliferating host cells. Ara-A$ is a nucleoside antibiotic having broad spectrum acti- 
vity against DNA viruses3 but with low toxicity to experimental animals4 and man.5 
The low toxicity probably is related to the rapid deamination of ara-A to the less 
active ara-Hx and its subsequent phosphorolysis to h~oxanth~ne.6,7 Since the S- 
triphosphate of ara-A appears to be the active form,8 the low toxicity also might be 
due to an inability of normal animal tissues to phosphorylate the drug. 
Mammalian erythrocytes commonly phosphorylate fraudulent nucleosides result- 
ing in a preferential uptake because the nucleoside is converted to the more ionized 
* Present address: Department of Pharmacology. Michigan State University, East Lansing, MI 48823, 
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1 Abbreviations used: ara-A. 9-P-o-arabinofuranosyladenine; ara-AMP, ara-ADP and ara-ATP, the 
corresponding 5’-mono-, di- and triphosphates of ara-A; ara-Hx, 9-/I-D-arabinofuranosylhypoxanthine; 
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and, therefore, less diffusable nucleotide. Drugs which are phosphorylated in this 
manner include arabinosyl cytosine,g 7-deaza-adenosine,” and ribosyl6-methylthio- 
purine.’ ’ It appeared that ara-A also could be phosphorylated in this way because 
the amount of label in erythrocytes rose slowly over several days after the 
administration of the labeled drug to several species of laboratory animals6 The 
studies in vitro reported here were undertaken to completely examine the uptake and 
phosphorylation of ara-A by rat and human erythrocyte preparations. 
EXPERIMENTAL 
Materials. Hypoxanthine, adenine and adenosine were purchased from CalBio- 
them., San Diego, California; inosine, IMP, ITP, AMP, ATP and dATP from Sigma 
Chemical Co., St. Louis, Missouri; ara-Hx from Pfanstiehl Laboratories, Waukegan, 
Illinois; 9-P-D-arabinofuranosyl-[2-3H]adenine (670 mCi/m-mole) and [8- 
i4C]adenosine (53 mCi/m-mole) from New England Nuclear Corp., Boston, Massa- 
chusetts; ara-ADP and ara-ATP from Terra Marine Bioresearch, La Jolla, Califor- 
nia; ara-A was a gift of Dr. H. Machamer, Parke, Davis & Co., Detroit, Michigan 
and ara-IMP and ara-AMP were gifts of Dr. R. L. Tolman, ICN Nucleic Acid 
Research Institute, Irvine, California. PEI-cellulose plates were obtained from Brink- 
mann Instruments, Inc., Des Plaines, Illinois. 
Uptake methods. Blood was obtained from male, albino, Sprague-Dawley rats by 
cardiac puncture after stunning the animal by a blow on the head. Blood from male, 
Rhesus monkeys was drawn from a saphenous vein. Blood from a normal, human 
male donor was obtained from the left cephalic vein. Blood was drawn into sterile, 
heparinized syringes and cooled immediately to O-4”. For uptake experiments, blood 
was incubated directly with C3H]ara-A for up to 4 hr at 37”. All incubations were 
performed in duplicate. Cells were sedimented by centrifugation at 5600 g for 10 min, 
and plasma and cells combusted in a Packard model 300 sample oxidizer. Radioacti- 
vity was assayed in a Packard model 3320 liquid scintillation spectrometer and dis./ 
min were determined by the external standard method. 
Lysate preparation and incubation For preparation of erythrocyte lysates, blood 
was centrifuged at 16009 for 10 min at 0” and buffy coat cells and plasma were 
removed. All subsequent procedures were performed at O-4”. Cells were washed three 
times by resuspension in an equal vol. 0.9% NaCl and hemolyzed by repeated rapid 
freezing in liquid nitrogen and thawing. After centrifugation at 6500 g for 10 min, the 
supernatant was dialyzed against 300 vol. 1 mM Tris buffer (pH 7.4) for 2 hr and 
either used immediately or frozen at - 80” and used within 2 months. 
Preparations from rat blood gave dialysates containing 8-12 mg/ml of protein as 
determined by the method of Lowry et a1.,12 whereas preparations from human 
blood contained approx. 150 mg/ml of protein. The difference in protein concn arose 
because the centrifugation step before dialysis did not pellet cell debris from human 
erythrocytes. 
Phosphorylation of ara-A and adenosine was examined using the conditions de- 
scribed by Lerner and Rubinstein.i3 Incubations were performed at 25” and con- 
tained 3 mg (rat) or 16 mg (human) protein, 2.5 mM MgCl,, 2.5 mM ATP and 
19 PM [ 14C]adenosine or C3H]ara-A in 1.0 ml of 50 mM phosphate buffer (pH 7.0). 
Aliquots were removed at the indicated times, mixed with an equal vol. 95% ethanol 
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at - 20“ and protein was precipitated overnight at - 20”. All incubations with ara-A 
and adenosine were performed twice. In a preliminary experiment, the use of stoi- 
chiometric quantities of [14C]adenosine and ATP resulted in a reduced yield of 
[14C]ATP but increased amounts of labeled ADP and AMP. 
Chromatographic anal~ws. Aliquots of the ethanol-containing supernatants were 
mixed with solutions of known reference compounds and characterized by TLC. 
Purines and nucleosides were determined as described previously.14 Thus, separation 
of arabinosyl nucleosides and purines was accomplished on Silica gel plates using 
chloroform~metha~~ol~3”,, acetic acid (3: 2: 1. v/v. lower phase) as the solvent. Ribosyl 
nucleosides and purines were chromatographed on Silica gel in a solvent consisting 
of 17 parts of chloroform-methanol-3% ammonia (3: 2: 1, v/v, lower phase) and three 
parts methanol. Nucleotides were not resolved in these systems and remained at the 
origin. Individual nucleotides were analyzed on PEI-cellulose plates using 2 N formic 
acid-2 M LiCl(1: 1, v/v) as described by Randerath and Randerath.” Prior develop- 
ment with water in the second dimension removed purines and nucleosides and per- 
mitted the complete resolution of ATP, ITP, ADP, IDP, AMP and IMP. AMP and 
IMP were differentiated from corresponding arabinosyl nucleotides by chromat- 
ography on PEI-cellulose plates in boric acid-saturated 1 M LiCl (pH 4.5tethanol 
(1: 1, v/v) according to Schrecker et al. I6 Under these conditions, IMP, AMP and 
all di- and triphosphates remained &ar the origin (RJ ‘v O.l), while corresponding 
deoxyribosyl and arabinosyl nucleoside monophosphates migrated with R, values 
around 0.3 (Table 1). Examination of developed plates under U.V. light (254 nm) 
revealed the reference compounds which appeared as dark spots. Radioactive meta- 
bolites were detected by cutting or scraping 2- or 5-mm sections of the gel into count- 
ing vials. extracting with 2 ml of a solution of 0.1 N HCI in methanol, adding 13 ml 
of a scintillation soln containing 3 g 2-(-4-rrrt-butylphenyl)-5-(4-biphenyl)-1,3,4-oxa- 
diazole/l. toluene and counting as indicated above. This procedure resulted in the 
quantitative recovery and detection of all compounds spotted on the plates. Coinci- 
dence of labeled and reference compounds in unambiguous systems was taken as in- 
dicating identity. 
RESULTS AND DISCUSSION 
Whole rat, monkey or human blood was incubated with 1OOpM C3H]ara-A for 
2 hr at 37” as a preliminary test of whether ara-A was phosphorylated by erythro- 
cytes. There was no accumulation of the drug by erythrocytes beyond an initial equi- 
libration of label between cells and plasma, i.e. the same number of dis./min were 
detected/unit vol. of each. Equilibration occurred during the first l-3 min of incuba- 
tion probably as a result of simple or facilitated diffusion.” Similar results were 
obtained after a 30-min incubation of rat or human blood with ara-A concn of O.l- 
100 PM. Labeled drug readily back diffused into the medium upon resuspension of 
cells in an equal vol. 0.9% NaCl. Four or five such washes completely removed the 
label from cells, indicating that little phosphorylation had occurred. In contrast, 7- 
deaza-adenosine ’ O and ribosyl-6-methylthiopurine’ 1 were reported to be completely 
cleared from plasma into erythrocytes during a similar 2-hr incubation. Label from 
these compounds was not washed from the cells because the nucleosides were con- 
verted to the mono-, di- or triphosphate level by erythrocyte enzymes. 
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In order to determine directly whether ara-A was phosphorylated by erythrocyte 
enzymes, lysates were prepared and incubated utilizing conditions detailed by Lerner 
and Rubinstein l3 These authors demonstrated the presence of adenosine kinase 
(EC 2.7.1.20) in ‘human erythrocytes. Miech and Santos” had previously demon- 
strated the presence of adenosine kinase in rat erythrocytes. As positive controls. rat 
and human erythrocyte lysates also were incubated with [i4C]adenosine. After incu- 
bation, deproteinized aliquots were analyzed for purines, nucleosides and total nu- 
cleotides using Silica gel chromatography systems and for individual nucleotides 
using PEI-cellulose chromatography. These experiments revealed the appearance of 
[i4C]ATP (Fig. 1) which is consistent with the phosphorylation of [i4C]adenosine 
by adenosine kinase and the subsequent conversion of AMP to the triphosphate.13 
The data of Fig. I also show the degradation of adenosine to inosine and hypoxan- 
thine followed by the reutilization of hypoxanthine to give IMP. The low amounts 
of adenosine at zero time were attributed to adenosine deaminase activity which 
occurred at O-4” before the first aliquot was removed. The phosphorylation and 
degradation of adenosine observed here is in accord with other reports of adenosine 
metabolism by erythrocyte lysates13 and platelet-rich plasma.” 
When [3H]ara-A was incubated under identical conditions with rat erythrocyte 
lysates, merely 2 per cent of the labeled drug was converted to nucleotides during 
a 2-hr incubation. Analysis on PEI-cellulose showed that most of the labeled nucleo- 
tides chromatographed with IMP and AMP, but the low amounts discouraged ad- 
ditional characterization. This is noteworthy because little nucleotide formation 
occurred despite the long half-life of ara-A in rat erythrocyte lysates (Fig. 2a). Dea- 
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FIG. 1. Metabolism of adenosine by erythrocyte lysates. Lysates from rat (a) and human (b) erythrocytes 
were incubated with 19 PM [‘VZ]adenosine, 2.5 mM Mg2+ and 2.5 mM ATP. Aliquots were removed at 
the indicated times, deproteinized and analyzed by TLC. Silica gel layers were spotted with 46W 
8300dis./min for the determination of nucleosides; PEI-cellulose layers were spotted with 360& 
7400 dis./min for the quantitation of nucleotides. 
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FIG. 2. Metabolism of ara-A by erythrocyte lysates. Lysates from rat (a) and human (b) erythrocytes were 
incubated with 19 PM C3H]ara-A, 2.5 mM Mg’+ and 2.5 mM ATP. Aliquots were removed at the indi- 
cated times, deproteinized and analyzed by TLC. Silica gel layers were spotted with 40,000-80,000 dis./min 
for nucleoside determinations; PEI-cellulose layers were spotted with 60,000-10O,OOOdis./min for nucleo- 
tide quantitation. 
half-iife was considerably shorter. The difference might be attributed to greater 
amounts of adenosine deaminase (EC 354.4) in the human erythrocyte lysates. This 
does not appear likely, however, as little difference was noted in the deamination rate 
of adenosine (Fig. 1). The observations agree with those of Koshiura and I&Page’* 
who found that rat and human erythrocytes deaminated adenosine at a similar rate, 
but human erythrocytes deaminated ara-A at a greater rate than rat erythrocytes. 
Somewhat greater amounts of nucleotides were detected in 2-hr incubations of 
human erythrocyte lysates with C3H]ara-A, but the rate of nucleotide synthesis was 
less than 10 per cent of that seen with adenosine. Extended incubation times and 
chromatography on Silica gel showed that after 4 hr 11 per cent, and after 18 hr 40 
per cent of the labeled ara-A had been converted to nucleotides (Fig. 2b). These nuc- 
leotide fractions were analyzed additionally by chromatography on PEI-cellulose 
plates. Chromatography in the formate solvent (Table 1) showed that after 4- and 
1%hr incubations most of the labeled nucleotides chromatographed coincident with 
IMP. Minor amounts of label also were associated with AMP, ADP, ATP, IDP and 
ITP. Arabinosyl nucleotides also migrated with these ribosyl nucleotides in the for- 
mate solvent; therefore, the borate-containing solvent was used to resolve the two 
sets of nucleotides. In this system nearly all nucleotide radioactivity chromato- 
graphed with a Rf value ~013, while ara-IMP and ara-AMP chromatographed 
with Rf values > 0.20 (Table 1). Thus the label associated with the inosine mononuc- 
leotides in the formate system represents IMP, not ara-IMP. Roughly 10 per cent 
of the nucleotides might be arabinosyl nucleotides because the borate-containing sol- 
vent would not resolve ATP, ADP, ITP and IDP from the corresponding arabinosyl 
nucleotides. This seems highly unlikely, however, as little ara-AMP was detected. 
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These conclusions also are supported by the kinetic data depicted in Fig. 2b, i.e. 
a precursor-product relationship exists between ara-Hx, not ara-A, and the nucleo- 
tides which were formed. Glycosidic cleavage of ara-Hx by purine nucleoside phos- 
phorylase (EC 2.4.2.1) and reutilization of the free hypoxanthine by hypoxanthine 
phosphoribosyltransferase (EC 2.4.2.8) to give IMP seems to be a likely pathway. The 
presence of active forms of these two enzymes in the lysate preparations was con- 
firmed by the kinetics of hypoxanthine and IMP formation from adenosine (Fig. 1 b). 
The formation of adenine nucleotides from IMP could follow during the more 
lengthy incubation period with ara-A via the purine ribonucleotide interconversion 
pathway (e.g. see Henderson and Paterson). 21 The detection of very limited amounts 
of adenine nucleotides agrees with the observations of Lowy et a1.22 that human 
erythrocytes have little capacity for the conversion of IMP to AMP. 
The present results also are consistent with the statement of Ilan et a1.23 that nor- 
mal mouse blood could not phosphorylate ara-A. In addition, they found that only 
12-18 per cent of ara-A accumulated by liver from normal or Plasmodium bergki-in- 
fected mice was converted to ara-AMP. Brink and LePagez4 observed nearly equal 
amounts of labeled nucleosides and nucleotides in the liver when [8-14C]ara-A was 
administered to mice. However, the nucleotides detected by both these groups were 
characterized by chromatography on Dowex-1 which would not distinguish between 
ribosyl and arabinosyl nucleotides. More recently LePage2’ found that label from 
[8-14C]ara-A and [8-14C]ara-Hx was incorporated into nucleotides and nucleic 
acids of TA3 cells. Most of the label from both nucleosides was incorporated as 
AMP, not ara-AMP, indicating that glycosidic cleavage had occurred followed by 
TABLE 1. CHARACTERIZATION OF LABELED NUCLEOTIDES FROM HUMAN ERYTHROCYTE LYSATES INCUBA~D 
WITH [3H]~~~-A* 
Nucleotide 
PEI-cellulose chromatography in: 
Formate solvent Borate solvent 
% label migrating % label migrating 
with nucleotide with nucleotide 
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<1 <1 @08 
0.10 
005 
86 90 0.21 1 1 
0.13 2 1 
3 1 0.31 
0.33 11 1.51 
* Deproteinized aliquots from the incubation described in Fig. 2B were chromatographed on PEI-ccllu- 
lose plates and developed in the listed solvents as described in the Experimental section. Approximately 
60.000 and 140,000 dis./min were chromatographed in the formate and borate solvents respectively. 
t Sum of label chromatographing with R, ~0.10. 
$I Sum of label chromatographing with ara-AMP and dAMP. 
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a reutilization of the labeled purine. Apparently TA3 cells possess an active purine 
ribonucleotide interconversion pathway so that IMP formed from hypoxanthine 
gives AMP as the final product. In human erythrocytes, this pathway is relatively 
inactive22 so that IMP accumulates. 
The lack of ara-A phosphorylation noted in this study also is consistent with 
studies which noted that ara-A is a poor substrate for partially purified adenosine 
kinase. Schnebli et ~1.~~ noted that the amount of ara-A phosphorylated by the 
kinase from an established line of human epidermoid carcinoma cells (HEp-2) was 
< 7 per cent of the amount of adenosine phosphorylated. Lindberg et a1.27 found that 
the rabbit liver enzyme had a K, for ara-A lOOO-fold greater than that for adenosine. 
Although ara-A exhibits at least one activity as the nucleoside, a tRNA methylase 
inhibitor,2 a conversion to the triphosphate has been assumed to be the requisite step 
in the formation of the active drug.8 The apparent paucity of ara-A phosphorylation 
by the limited number of normal tissues examined raises the possibility that the lack 
of toxicity to normal animals4 and man5 may be related to the lack of conversion 
of ara-A to ara-ATP by host animals. 
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